PDCD1 and neoplasm: While the small numbers in each subgroup preclude definitive conclusions, our results raise the hypothesis that baseline tumor stage could serve as a useful biomarker for selecting patients most likely to benefit from treatment intensification with PD−1 inhibitors in the neoadjuvant chemoradiation setting.